Cooperative Agreement R43TR001906

This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $1,617,565.00 to New York University (NYU) to develop a modular toolbox of protein and lipid hybrid biomaterials for the delivery of short interfering RNA (siRNA) sequences. The goal is to construct a hybrid nanovehicle, termed a lipoproteoplex (LPP), that can...

This SBIR Phase I award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to develop a novel topical therapeutic for the treatment of psoriasis. The key objectives are to: 1) characterize the therapeutic efficacy of the new treatment in a mouse model of psoriasis, 2) develop a topical drug product formulation and test its...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Arizona a $216,759 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a transdermal nanoemulsion-based gel formulation containing the antiretroviral drugs dolutegravir and rilpivirine for the long-term treatment of pediatric HIV infection. The research aims to address challenges with existing pediatric HIV formulations, such as poor adherence, by creating a...

This Project Grant award for $506,451 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) aims to develop an effective targeted delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases, including Alzheimer's disease. The project leverages the awardee's 3P Biotechnologies, Inc.'s expertise in exosome engineering, drug delivery, and siRNA therapeutics. The key products or services to be delivered under this award...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $835,417 to the Icahn School of Medicine at Mount Sinai to develop novel lipid nanoparticle (LNP) formulations for efficient delivery of nucleic acid-based therapeutics to the brain to treat Alzheimer's disease (AD). The key objectives are to: 1) synthesize innovative blood-brain barrier (BBB)-crossing lipids and formulate a library of LNPs, 2) engineer siRNA and mRNA sequences to modulate...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund the development of a 3D human skin model with CRISPR/Cas9 gene knockouts to investigate interactions between the skin microbiome and skin cell populations. The $198,782 award to Duke University will enable the creation of 3D reconstructed human epidermis (RHE) cultures with knocked-out...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,700 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of California, Irvine. This grant will fund the development and characterization of recombinant, cell-penetrating botulinum protease variants that can inhibit the release of neuropeptides and cytokines in neurons and immune cells, respectively. The goal is to create a new topical therapeutic...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award in the amount of $304,450 provides funding to Lybra Bio Inc. for the development of a microneedle-based platform to treat autoimmune skin diseases. The project aims to advance a hydrogel-based microneedle patch that can effectively deliver therapeutics through the skin to address conditions like alopecia areata, vitiligo, and psoriasis. The key goals are to modulate the drug...

This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $595,117 to Vanderbilt University to develop carrier-free siRNA conjugates as disease-modifying osteoarthritis drugs. The project aims to (1) elucidate the mechanism of action of siRNA-L2 against MMP13 in osteoarthritis, (2) test new chemical modifications to improve joint retention...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $949,062 to Somatoceutics LLC to develop a novel peptide-based nanoparticle drug delivery system to improve the penetration of therapeutics across the blood-brain barrier for the treatment of Alzheimer's disease and related dementias. The key objectives are to 1) optimize the assembly, drug-loading, and blood-brain barrier transcytosis of the SMC-101 nanotubes in vitro, and 2) evaluate the...